The company has received this permission after successfully completing the clinical trial on 125 patients across 8 clinical trial centers within India.
Lyka Labs is one of the pioneers in the field of manufacturing of pharmaceutical formulations & active pharmaceutical ingredients [APIs] across various therapeutic segments.
The company reported a consolidated net loss of Rs 1.85 crore in the quarter ended June 2023 as against net profit of Rs 0.60 crore during the previous quarter ended June 2022. Sales declined 16.77% to Rs 22.88 crore in Q1 FY24 over Q1 FY23.